The Future of Biology is Digital

It is already happening. The ubiquity of compute and access to Large Language Models (LLMs) has changed things forever. Here is where we see the largest opportunities.

We staked SciSpot, our first investment out of Breakwater, on the premonition that biotech data is fundamentally broken. As we have spent more time understanding the space and opportunity, we truly believe that AI, automation, and data science will rapidly transform our understanding of drug development, testing, and production.

It is already happening. The ubiquity of compute and access to Large Language Models (LLMs) has changed things forever. Here is where we see the largest opportunities.

Data Integration and Analysis: The integration of diverse datasets, computational advancements, and innovative algorithms marks a significant stride in drug discovery, reminiscent of the AI revolution. This integration facilitates the development of new datasets, like intricate brain maps and extensive cell libraries. The shift towards cloud-based infrastructure reflects a trend towards more efficient data processing, enhancing the ability to handle vast amounts of scientific data. The use of LLMs in early discovery stages has opened new avenues for processing scientific literature, uncovering new mechanisms, and identifying potential disease targets, illustrating the critical role of data in modern drug discovery.

  • Scispot is a dynamic AI toolkit designed to integrate and transform R&D data

Advancements in Drug Discovery: The application of AI in biology, exemplified by breakthroughs like Google DeepMind's AlphaFold, represents a new era in addressing complex biological challenges. This innovation has led to a surge in the use of cloud computing for large-scale compound analysis, essential for navigating the extensive chemical space in search of specific, effective molecules. Enhancing the accuracy of molecular simulations is pivotal for ensuring that experimental outcomes closely mirror predictions. The expansion of AI applications in various drug discovery stages, from laboratory automation to clinical trial design, underscores the evolving role of AI in transforming traditional pharmaceutical approaches.

  • Psivant Therapeutics is a biotechnology company that's revolutionizing drug discovery by employing a physics-driven approach to design novel small molecule therapeutics.
  • AlphaFold, developed by Google DeepMind, is an AI program that has made a breakthrough in predicting protein structures

Evolution of Testing Methods: Automated laboratories are reshaping experimentation, focusing on lowering costs, increasing throughput, and improving consistency and reliability. This evolution is part of a broader trend towards AI-powered drug discovery, promising a future where automated, AI-driven approaches surpass traditional methods. This shift aims to yield more efficient, cost-effective, and impactful medications, marking a significant transformation in preclinical drug discovery. The vision for AI in drug testing suggests a future with reduced reliance on traditional methods (i.e. animal testing), paving the way for more advanced and accurate testing standards. We strongly believe digital biology has the potential to significantly reduce, and in some cases, replace animal testing.

  • Nortis Bio is a biotechnology company known for developing advanced microfluidic organ-on-a-chip technology, which allows for more effective and efficient drug testing and disease modeling by replicating human organ systems on a microscale.
  • How One Texas County Is Fighting 43,000 Monkeys

Production: AI will help to streamline the process of identifying and synthesizing effective compounds, leading to more efficient and scalable manufacturing processes. Additionally, they can improve the predictability and optimization of drug formulations, potentially reducing the time and resources needed for production, and ultimately enhancing the overall efficiency of the drug manufacturing pipeline. 

We are not alone in our summations:

"Where do I think the next amazing revolution is going to come? And this is going to be flat out one of the biggest ones ever. There's no question that digital biology is going to be it." - Jensen Huang, founder & CEO of NVIDIA.

Back to Journal